The following studies are being carried out at the Somerset Foundation Trust.
ASPECT – Aspirin after hospitalisation with Pneumonia to prevent cardiovascular Events randomised Controlled Trial
ASSESS-MESO (TILT) COHORT STUDY – A prospective observational cohort study examining the natural history of mesothelioma, exploring potential biomarkers and factors that may predict outcome, as well as providing a resource for future trials within a cohort. TILT Cohort study
CHORUS – multi-centre double-blind randomised placebo-controlled group-sequential superiority trial to assess the effectivenessand cost-effectiveness of oral Corticosteroids in patients witH fibrOtic hypeRsensitivity pneUmonitiS
EPIC-HFT – Effect of Home High-Flow Therapy vs. Usual Care on Hospital Readmission or Death After an Acute Chronic Obstructive Pulmonary Disease (COPD) Exacerbation: a UK-Based Multicentre Randomised Clinical Trial
SELF-BREATHE – A multicentre, randomised controlled trial comparing usual NHS care to a self-guided internet-based intervention plus usual NHS care to reduce breathlessness in adults living with chronic breathlessness
OPACE – Optimising azithromycin prevention treatment in COPD to reduce exacerbations : A double blind adaptive design pragmatic phase IV randomised controlled trial
PRESIDE – Prospective study of antimicrobial RESIstance in chronic lung DiseasE
RAPID – Rescue packs post-discharge in chronic obstructive pulmonary disease: An open-label multicenter randomisedcontrolled trial
SBIVA – Seven versus Fourteen Days Antibiotics for Patients with Bronchiectasis Requiring Intravenous Antibiotics
ASTHMA GENETICS – Screening of target genes for polymorphic variation which may alter treatment response for airway management
TIPAL – The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial
If you would like any information about these trials please email:
Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole
Idiopathic Pulmonary Fibrosis is a disease which results in damage to the lung tissue. It is characterised by progressive loss of lung function (measured by breathing tests) and increasing breathlessness. It is incurable and there are few available treatments. It is thought to occur because of tiny scarring (which we call fibrosis) that develop throughout the lungs.
These breathing tests include spirometry assessments, which measure the amount of air you can breathe out and how fast you can blow it out. Spirometry tests can be carried out at hospital, GP surgeries or your home provided you have the correct equipment and appropriate training. These tests are completed regularly to monitor patient’s lung function.
Previous research suggests that idiopathic pulmonary fibrosis progresses slower if patients regularly take anti-acid drugs (like lansoprazole) and they may be likely to survive longer. Such drugs reduce acid which is thought to cause the scar formation and/or may directly reduce the amount of scar tissue. This is why people are often prescribed these drugs, but we don’t really know if they benefit patients; the aim of our study is to find this out.
We plan to recruit 298 participants with idiopathic pulmonary fibrosis from different regions of the UK. We want to know whether lansoprazole, when given alongside current treatments, slows down the decline in lung function which is associated with idiopathic pulmonary fibrosis.
